Publications by authors named "Kochung Lin"

Claim this Profile
N
Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial.
Yi-Wen Huang, Albert Qin, Jane Fang, Ting-Fang Wang, Chung-Wei Tsai, Ko-Chung Lin

Br J Clin Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The preeminence of clusters.
Fritz Bühler, C Mark Tang, Pratik Shah, Mark Leuchtenberger, Ko-Chung Lin

Nat Biotechnol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists.
Chi B Vu, William F Kiesman, Patrick R Conlon, Ko-Chung Lin, Melissa Tam

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-terminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model.
Darren P Baker, Edward Y Lin, Kochung Lin, Maria Pellegrini, Russell C Petter, Ling Ling Chen, Daniel J Lindner

Bioconjug Chem· September 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule very late antigen-4 antagonist can inhibit ovalbumin-induced lung inflammation.
Gloria C Koo, Kashmira Shah, Gloria J F Ding, Jianying Xiao, Richard Wnek, Ko-Chung Lin

Am J Respir Crit Care Med· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3D QSAR (COMFA) of a series of potent and highly selective VLA-4 antagonists.
Juswinder Singh, Herman van Vlijmen, Wen-Chemg Lee, Yusheng Liao, Ko-Chung Lin

J Comput Aided Mol Des· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis